Q-omics provides the consensus-scored TTLL11 profile across patient tissues and cancer cell-line models. TTLL11 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTLL11 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, TTLL11 RNA expression shows 20,365 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, KICH, and ACC as cancer lineages where TTLL11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTLL11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTLL11 survival associations across molecular data types. TTLL11 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTLL11 RNA expression–survival associations across cancer types. High TTLL11 expression shows unfavorable associations in ACC, LIHC and BLCA, but favorable associations in KIRC, THYM and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTLL11 RNA expression.
This table summarizes TTLL11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TTLL11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTLL11 shows lower tumor expression in KICH, THCA, BLCA, LUAD, UCEC and LUSC. The KICH box plot shows higher TTLL11 RNA expression in normal versus tumor tissue (log2 FC = −0.829, t-test p < 0.001).
This table shows molecular features associated with TTLL11 in patient tissues and cancer cell lines. In patient samples, TTLL11 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTLL11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LUNG_NSCLC_LUAD.
